Business Description
Royalty Pharma PLC
NAICS : 541714
SIC : 2833
ISIN : GB00BMVP7Y09
Share Class Description:
FRA:RPD: Class ATotal Employee Number:
100Compare
Compare
Traded in other countries / regions
RPRX.USARPD.GermanyRPRXN.Mexico IPO Date
2020-10-13Description
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.16 | |||||
Equity-to-Asset | 0.35 | |||||
Debt-to-Equity | 1.3 | |||||
Debt-to-EBITDA | 5.27 | |||||
Interest Coverage | 4.93 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 2.15 | |||||
Beneish M-Score | -2.94 | |||||
WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -6.2 | |||||
3-Year EBITDA Growth Rate | 44.2 | |||||
3-Year EPS without NRI Growth Rate | 8 | |||||
3-Year FCF Growth Rate | -3.4 | |||||
3-Year Book Growth Rate | 6 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 6.71 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 14.32 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 59.76 | |||||
9-Day RSI | 57.87 | |||||
14-Day RSI | 58.16 | |||||
3-1 Month Momentum % | 13.38 | |||||
6-1 Month Momentum % | 39.39 | |||||
12-1 Month Momentum % | 49.9 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.66 | |||||
Quick Ratio | 2.66 | |||||
Cash Ratio | 2.59 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 1.65 | |||||
Dividend Payout Ratio | 0.49 | |||||
3-Year Dividend Growth Rate | 5 | |||||
Forward Dividend Yield % | 1.72 | |||||
5-Year Yield-on-Cost % | 3.92 | |||||
3-Year Average Share Buyback Ratio | 1.1 | |||||
Shareholder Yield % | -0.53 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | 67.93 | |||||
Net Margin % | 33.9 | |||||
EBITDA Margin % | 69.66 | |||||
FCF Margin % | 106.89 | |||||
OCF Margin % | 106.89 | |||||
ROE % | 12.6 | |||||
ROA % | 4.37 | |||||
ROIC % | 9.23 | |||||
3-Year ROIIC % | 19.54 | |||||
ROCE % | 9.35 | |||||
Years of Profitability over Past 10-Year | 9 | |||||
Moat Score | 8 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 31.34 | |||||
Forward PE Ratio | 10.57 | |||||
PE Ratio without NRI | 30.68 | |||||
PS Ratio | 12.89 | |||||
PB Ratio | 3.62 | |||||
Price-to-Tangible-Book | 4.19 | |||||
Price-to-Free-Cash-Flow | 12.03 | |||||
Price-to-Operating-Cash-Flow | 12.03 | |||||
EV-to-EBIT | 20.97 | |||||
EV-to-Forward-EBIT | 21.58 | |||||
EV-to-EBITDA | 20.91 | |||||
EV-to-Forward-EBITDA | 21.58 | |||||
EV-to-Revenue | 14.57 | |||||
EV-to-Forward-Revenue | 12.96 | |||||
EV-to-FCF | 13.61 | |||||
Price-to-GF-Value | 1.5 | |||||
Price-to-Projected-FCF | 1.1 | |||||
Price-to-Graham-Number | 2.39 | |||||
Earnings Yield (Greenblatt) % | 4.77 | |||||
FCF Yield % | 10.47 | |||||
Forward Rate of Return (Yacktman) % | 11.13 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Royalty Pharma PLC Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 2,097.446 | ||
| EPS (TTM) (€) | 1.541 | ||
| Beta | 0.4019 | ||
| 3-Year Sharpe Ratio | 0.6 | ||
| 3-Year Sortino Ratio | 1.06 | ||
| Volatility % | 18.4 | ||
| 14-Day RSI | 58.16 | ||
| 14-Day ATR (€) | 0.834843 | ||
| 20-Day SMA (€) | 46.756 | ||
| 12-1 Month Momentum % | 49.9 | ||
| 52-Week Range (€) | 28.87 - 49 | ||
| Shares Outstanding (Mil) | 443.27 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Royalty Pharma PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Royalty Pharma PLC Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-05 08:00 | In 130 days | ||
| Third quarter earnings results for 2026 | 2026-11-05 | In 129 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-06 08:00 | In 39 days | ||
| Second quarter earnings results for 2026 | 2026-08-06 | In 38 days | ||
| Goldman Sachs 47th Annual Global Healthcare Conference | 2026-06-09 16:00 | 48.00 (+0.23%) | ||
| General meeting for 2026 | 2026-06-04 09:00 | 46.00 (+1.10%) | ||
| Guidance call for 2026 | 2026-05-19 10:00 | 44.50 (+0.00%) | ||
| USD 0.235000 Cash Dividend | 2026-05-15 | 45.14 (+0.00%) | ||
| Guidance call for 2026 | 2026-05-13 13:40 | 44.80 (+3.11%) | ||
| First quarter earnings conference call for 2026 | 2026-05-06 08:00 | 41.91 (-1.65%) |
Show
Entries
Royalty Pharma PLC Frequently Asked Questions
What is Royalty Pharma PLC(FRA:RPD)'s stock price today?
The current price of FRA:RPD is €47.47. The 52 week high of FRA:RPD is €49.00 and 52 week low is €28.87.
When is next earnings date of Royalty Pharma PLC(FRA:RPD)?
The next earnings date of Royalty Pharma PLC(FRA:RPD) is 2026-08-06 Est..
Does Royalty Pharma PLC(FRA:RPD) pay dividends? If so, how much?
The Dividend Yield %  of Royalty Pharma PLC(FRA:RPD) is 1.65% (As of Today), Highest Dividend Payout Ratio of Royalty Pharma PLC(FRA:RPD) was 0.55. The lowest was 0.33. And the median was 0.46. The  Forward Dividend Yield % of Royalty Pharma PLC(FRA:RPD) is 1.72%. For more information regarding to dividend, please check our Dividend Page.
Press Release
Articles on Royalty Pharma PLC
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers